% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Georgi:309656,
      author       = {J.-A. Georgi and C. Röllig and J. Schetelig and C. Thiede
                      and S. Brückmann and M. Bornhäuser$^*$ and J. M. Middeke},
      title        = {{R}elapse following {FLT}3 inhibitor cessation in
                      {FLT}3-{ITD}-positive {AML}: lessons from two clinical
                      cases.},
      journal      = {Annals of hematology},
      volume       = {105},
      number       = {3},
      issn         = {0939-5555},
      address      = {New York},
      publisher    = {Springer},
      reportid     = {DKFZ-2026-00288},
      pages        = {82},
      year         = {2026},
      note         = {#NCTZFB9#},
      abstract     = {The clinical success of FLT3 inhibitors has led to their
                      steadily increasing use in the treatment of acute myeloid
                      leukemia (AML), both in the relapsed/refractory setting and
                      as post-transplant maintenance. Despite their expanding
                      application, there is currently no guidance on the optimal
                      duration of therapy or the feasibility of discontinuation.
                      In the maintenance context, current practice is largely
                      based on trial protocols with predefined treatment periods,
                      yet relapses after cessation have been documented.
                      Similarly, in the relapsed/refractory setting, the
                      management of long-term responders to FLT3-directed
                      monotherapy lacks evidence-based guidance.We report two
                      cases of FLT3-ITD AML patients with relapse after
                      discontinuation of prolonged FLT3 inhibitor therapy, despite
                      sustained remission prior to withdrawal. As such scenarios
                      remain insufficiently characterized in the literature, these
                      case vignettes are presented to highlight the unresolved
                      challenge of defining the appropriate duration of FLT3
                      inhibitor therapy and to underscore the need for systematic
                      evaluation to establish evidence-based strategies for safe
                      discontinuation or extended administration.},
      keywords     = {Humans / fms-Like Tyrosine Kinase 3: antagonists $\&$
                      inhibitors / fms-Like Tyrosine Kinase 3: genetics /
                      Leukemia, Myeloid, Acute: drug therapy / Leukemia, Myeloid,
                      Acute: genetics / Male / Middle Aged / Protein Kinase
                      Inhibitors: administration $\&$ dosage / Protein Kinase
                      Inhibitors: therapeutic use / Recurrence / Female / Adult /
                      FLT3 inhibitor (Other) / FLT3-ITD AML (Other) / Gilteritinib
                      (Other) / Measurable residual disease (MRD) (Other) /
                      Post-transplant maintenance (Other) / Relapse (Other) /
                      fms-Like Tyrosine Kinase 3 (NLM Chemicals) / FLT3 protein,
                      human (NLM Chemicals) / Protein Kinase Inhibitors (NLM
                      Chemicals)},
      cin          = {DD04},
      ddc          = {610},
      cid          = {I:(DE-He78)DD04-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41636849},
      doi          = {10.1007/s00277-026-06776-w},
      url          = {https://inrepo02.dkfz.de/record/309656},
}